AB Science announces a slight delay in the publication of its 2025 half-year financial report




AB Science announces a slight delay in the publication of its 2025 half-year financial report

PRESS RELEASE

AB SCIENCE ANNOUNCES A SLIGHT DELAY IN THE PUBLICATION OF ITS 2025 HALF-YEAR FINANCIAL REPORT

THE COMPANY WILL PUBLISH ITS HALF-YEAR FINANCIAL REPORT FOR 2025 ON OCTOBER 10, 2025, AT THE LATEST

Paris, September 30 2025, 6.30pm CET

AB Science SA (Euronext – FR0010557264 – AB) today announced that it has postponed the publication of its financial report for the first half of 2025, initially scheduled for 30 September 2025, to give the auditors time to complete their audit work.

The Company will publish its financial report for the first half of 2025 on Friday 10 October 2025, at the latest.

About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment.

AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science’s website: www.ab-science.com.

Forward-looking Statements – AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend”, “estimate” or “plan” as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

For additional information, please contact:

AB Science
Financial Communication & Media Relations
investors@ab-science.com

Attachment

• CP Décalage Publication Comptes 2025 S1 VEng VF

IPSEN – Buy-back programme – Art 5 of MAR – Week 39 – 2025




IPSEN – Buy-back programme – Art 5 of MAR – Week 39 – 2025

Attachment

• EN_IPSEN – Buy-back programme – Art 5 of MAR – Week 39_2025

Clinical Match Me Announces Strategic Partnership with NPACE




Clinical Match Me Announces Strategic Partnership with NPACE

Clients to Benefit from Exclusive Discounts and Enhanced Educational Opportunities

San Juan, PR, Sept. 30, 2025 (GLOBE NEWSWIRE) — Clinical Match Me, a transformative force in Nurse Practitioner education, NP preceptor placement and job placement for healthcare professionals, is pleased to announce a strategic partnership with the Nurse Practitioner Associates for Continuing Education (NPACE). This collaboration marks a significant milestone in Clinical Match Me’s mission to empower Nurse Practitioner students, preceptors, and healthcare education institutions.

Nurse Practitioner Associates for Continuing Education

Through this partnership, Clinical Match Me clients will now enjoy a 20% discount on NPACE services, enhancing their access to high-quality continuing education resources. This exclusive offer underscores Clinical Match Me’s commitment to providing comprehensive support to its clients, ensuring they have the tools and opportunities necessary to excel in their professional journeys.

NPACE, renowned for its dedication to providing evidence-based educational programs, aligns perfectly with Clinical Match Me’s vision of fostering long-lasting relationships and guiding clients through every step of their careers. By becoming an official education partner of NPACE, Clinical Match Me further solidifies its position as a leader in the healthcare education sector.

“This partnership with NPACE is a testament to our dedication to offering unparalleled resources and opportunities to our clients,” said Brad Konia, CEO of Clinical Match Me. “We are excited to provide our clients with access to NPACE’s esteemed educational services, which will undoubtedly enhance their professional development and success.”

Clinical Match Me continues to innovate and expand its offerings, providing preceptor placement, job placement for travel nurses, and now continuing education through its partnership with NPACE. This partnership is yet another step in Clinical Match Me’s ongoing efforts to support healthcare education and APP schools in shaping the future of healthcare.

By offering affordable credentialing and a unique staffing solution, Clinical Match Me grants healthcare facilities early access to a talent pool of providers while they are still in school. This allows facilities to evaluate candidates during clinical rotations and hire top talent before they graduate, giving them a competitive edge in the healthcare industry. Clinical Match Me also offers practicing healthcare providers the opportunity to become a preceptor and earn substantial honorariums (typically $1,000+ per rotation) while helping to train the next generation of providers.

APP schools benefit from Clinical Match Me’s outsourced preceptor placement, allowing them to focus on their core mission of educating the next generation of healthcare providers. The partnership with NPACE further enhances these offerings, providing students and professionals with additional resources to succeed.

For more information about Clinical Match Me and its partnership with NPACE, please visit their respective websites.

About Clinical Match Me

Clinical Match Me provides a Nurse Practitioner preceptor matching service that distinguishes itself through a personalized, technology-driven approach and student-friendly policies. Students sign up and submit placement requests for free, paying nothing until they accept a preceptor’s offer…a transparent, zero-risk process. The platform’s proprietary system instantly matches requests with preceptors, while a secondary outreach feature recruits out-of-network providers for difficult placements, maximizing successful matches. Offers are all-inclusive, covering both fees and honorarium, with flexible payment plans up to 24 months. Clinical Match Me uniquely allows students to review preceptor information, conduct interviews, and choose among multiple offers without upfront costs. A robust money-back guarantee protects students if their school rejects the preceptor or the preceptor cancels. With over a decade of industry leadership and hundreds of five-star reviews, Clinical Match Me combines affordability, automation, and personalized service for a superior student experience. 

Press inquiries

Clinical Match Me
https://www.clinicalmatchme.com
Brad Konia
brad@clinicalmatchme.com
787-356-9000
1666 Ave Ponce de Leon
San Juan, PR 00909

Sequana Medical’s alfapump® System Featured in Presentation at 2025 Portal Intervention Symposium




Sequana Medical’s alfapump® System Featured in Presentation at 2025 Portal Intervention Symposium

Dr. Rahul Patel of Icahn School of Medicine at Mount Sinai presented “alfapump®: Totally Implantable Peritoneal Drain Pump with Urinary Bladder Drainage”

Ghent, Belgium – September 30, 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announced that the alfapump® System was featured in a podium presentation at the 2025 Portal Intervention Symposium in Chicago, IL. The presentation, titled “alfapump®: Totally Implantable Peritoneal Drain Pump with Urinary Bladder Drainage,” focused on the surgical and technical aspects of the alfapump implant procedure for interventional radiologists.

Dr. Rahul Patel, Assistant Professor of Radiology and Surgery, Icahn School of Medicine at Mount Sinai, who presented at the symposium, commented: “The alfapump system represents a significant advancement in the management of recurrent or refractory ascites due to liver cirrhosis. From an intervention perspective, the implant procedure builds on established interventional radiology techniques while providing patients with a new treatment option. The ability to continuously and automatically remove ascites from the abdomen into the bladder offers our patients freedom from the burden of repeated large volume paracentesis procedures.”

Dr. Gijs Klarenbeek, Chief Medical Officer of Sequana Medical, continued: “We are delighted to see the alfapump system featured at this important specialty conference for the interventional radiology community. This presentation will raise awareness of the alfapump amongst the interventional radiologist community and is key in ensuring they have the knowledge and confidence to offer this innovative device to their patients. For too long, many patients with recurrent or refractory ascites due to liver cirrhosis have had to put up with a standard of care that has changed little in over 2,000 years. The alfapump is a 21^st century solution recognising that cirrhosis is increasingly a mainstream disease and patients are demanding and deserving better treatment options.”

The alfapump® system received U.S. FDA Premarket Approval in December 2024 for the treatment of recurrent or refractory ascites due to liver cirrhosis. It is the first active implantable medical device in the U.S. that automatically and continuously removes ascites from the abdomen into the bladder.

For more information, please contact:

Sequana Medical
Investor relations
E: IR@sequanamedical.com
T: +44 (0) 797 342 9917

Media Relations:
Jon Yu
ICR Healthcare
E: Sequana@icrhealthcare.com
T: +1 (646) 677-1855

Important Safety Information:

Indication for Use: The alfapump® System is intended for single patient use only in adult patients with refractory or recurrent ascites due to liver cirrhosis. It is indicated for the removal of excess peritoneal fluid from the peritoneal cavity into the bladder, where it can be eliminated through normal urination.

Contraindications: MRI Safety Information: The alfapump® System is MRI unsafe. This diagnostic procedure is contraindicated due to possible movement of the alfapump®, damage to the pump circuitry, tissue damage in the vicinity of the alfapump® and/or catheter dislocation. Hyperbaric oxygen therapy is contraindicated because the environmental conditions entailed in this therapy are out of the defined range of use for the alfapump® System.

Warnings, Risks, and Precautions: The implantation of the alfapump® may result in infection that could delay liver transplant or impact transplant listing status. Additional risks associated with implanting the alfapump® System including risk of peritoneal cavity infections/peritonitis, Coagulopathy, Small bladder capacity and/or obstructive uropathy.  The following procedures or therapies could impact the alfapump® System function: Supersonic therapy and high-frequency heat therapy, Transcutaneous Electrical Nerve Stimulation (TENS), Lithotripsy, Defibrillation, Radiation therapy, Electrocautery, or use of other implantable medical devices and wearable devices.

Adverse Events: In addition to procedure related risks the following Adverse Events may occur: pump pocket hematoma, skin erosion, infection, pump migration, catheter clogging or other catheter complications resulting in tissue damage or loss of or change in therapy, genito-urinary complications, reduced kidney function, hepatic encephalopathy, progression of liver disease, and other systemic effects.

Caution: the law restricts the sale by or on the order of a physician. Refer to package insert provided with the product for complete Instructions for Use, Contraindications, Potential Adverse Effects, Warnings and Precautions prior to using this product.

The alfapump® System is currently not approved in Canada.

DSR® therapy is still in development and is currently not approved in any country. The safety and effectiveness of DSR® therapy has not been established.

Note: alfapump® and DSR® are registered trademarks.

About Sequana Medical

Sequana Medical NV is a pioneer in treating fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. This causes major medical issues including increased mortality, repeated hospitalizations, severe pain, difficulty breathing and restricted mobility. Although diuretics are standard of care, they become ineffective, intolerable or exacerbate the problem in many patients. There are limited effective treatment options, resulting in poor clinical outcomes, high costs and a major impact on their quality of life. Sequana Medical is seeking to provide innovative treatment options for this large and growing “diuretic resistant” patient population. alfapump® and DSR® are Sequana Medical’s proprietary platforms that work with the body to treat diuretic-resistant fluid overload, and are intended to deliver major clinical and quality of life benefits for patients, while reducing costs for healthcare systems.

The Company received US FDA approval for the alfapump System for the treatment of recurrent or refractory ascites due to liver cirrhosis in December 2024, following the grant of FDA Breakthrough Device Designation in 2019. In Sequana Medical’s POSEIDON study, a landmark study across 18 centers in the US and Canada, the pivotal cohort of 40 patients implanted with the alfapump showed at 6 and 24 months post-implantation the virtual elimination of therapeutic paracentesis and an improvement in quality of life^1,2.

Sequana Medical has commenced US commercialisation through a small specialty salesforce initially targeting US liver transplant centers – 90 of these centers perform more than 90% of US liver transplants annually. CMS has approved the New Technology Add-on Payment for the alfapump when performed in the hospital inpatient setting as of October 1, 2025.

Results of the Company’s RED DESERT and SAHARA proof-of-concept studies in heart failure published in European Journal of Heart Failure in April 2024 support DSR’s mechanism of action as breaking the vicious cycle of cardiorenal syndrome. All three patients from the non-randomized cohort of MOJAVE, a US randomized controlled multi-center Phase 1/2a clinical study, have been successfully treated with DSR, resulting in a dramatic improvement in diuretic response and virtual elimination of loop diuretic requirements.³ The independent Data Safety Monitoring Board approved the start of the randomized MOJAVE cohort of up to a further 30 patients, which is dependent on securing additional financing.

Sequana Medical is listed on the regulated market of Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com.

Forward-looking statements

This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

¹ alfapump system SSED (summary of safety and effectiveness) PMA 230044
² as defined by subjective physical health (assessed by SF-36 PCS) and ascites symptoms (assessed by Ascites Q)
³ Data reported in press release of March 25, 2024; mean increase of 326% in six-hour urinary sodium excretion at 3 months follow up vs baseline, and 95% reduction of loop diuretics over same period

Attachments

• 20250930 Press Release Sequana Medical – Portal Intervention Symposium (ENG)
• 20250930 Press Release Sequana Medical – Portal Intervention Symposium (NL)

Major Wellbeing Organization Selects Aino’s SaaS Platform




Major Wellbeing Organization Selects Aino’s SaaS Platform

Aino Health AB (publ) has signed an agreement—facilitated through its occupational health collaboration partner Työterveys Aalto Occupational Health Care —with a leading wellbeing sector organization, covering 11,000 employees. The implementation of Aino’s SaaS platform is planned to begin within 2025, aiming to enhance proactive work ability management and employee well-being across the organization. 

“We are honored to support this organization in their mission to improve employee health and reduce work-related risks,” says Jyrki Eklund, CEO of Aino Health. “This partnership reflects the growing demand for data-driven solutions in the wellbeing industry.” 

Through the Aino platform, the organization will gain access to: 

• Real-time health and productivity data 

• Automated early support processes 

• Tools for identifying root causes of health challenges 

These capabilities are designed to reduce sickness absences, improve operational efficiency, and foster a culture of proactive employee support. 

This agreement marks a significant step in Aino Health’s strategic expansion into the wellbeing sector and reinforces its position as a leading provider of health management solutions in Europe. 

For more information 
Jyrki Eklund, CEO Aino Health 
Phone: +358 40 042 4221 
Email: jyrki.eklund@ainohealth.com 

Certified Adviser 
DNB Carnegie Investment Bank AB 
More info: https://investors.ainohealth.com/certified-adviser/

About Aino Health (publ) 
Aino Health is the leading provider of Software as a Service (SaaS) solutions for Corporate Health Management. Our platform helps organizations reduce sickness absences, identify root causes of health challenges, and systematize proactive support for employees. For more information, please visit ainohealth.com. 

Thousands of State of Georgia employees walk 880 million steps to benefit Title I schools




Thousands of State of Georgia employees walk 880 million steps to benefit Title I schools

State Health Benefit Plan members come together to help young Georgians in their communities while improving their personal health

‘Jump Shot for Health’ awards winning schools new sports equipment and renovated basketball courts; initiative made possible by Sharecare, Anthem Blue Cross and Blue Shield of Georgia, CVS Caremark, United Healthcare, Good Sports, and the Atlanta Hawks

ATLANTA, Sept. 30, 2025 (GLOBE NEWSWIRE) — Sharecare and Anthem Blue Cross and Blue Shield of Georgia jointly announced today the winners¹ of Jump Shot for Health, a four-month statewide steps challenge that encouraged State Health Benefit Plan (SHBP) members to engage in daily movement while supporting Georgia Title I schools².

Open to all members of the Be Well SHBP® well-being program — including public school teachers, bus drivers, cafeteria workers, state agency employees, and legislators as well as members’ covered dependents — Jump Shot for Health ran from January 15 through May 15, 2025. Over that time, participants tracked their daily steps through the Sharecare app, and allocated them to one of 27 participating school “teams.” At the conclusion of the challenge, more than 2,600 Georgians logged nearly 880 million steps, with 12 percent of participants surpassing one million steps individually.

“Throughout the Jump Shot for Health challenge, we were blown away by how passionately SHBP members across the state stepped up and set such an important example of what it means to share care – for yourself as well as the communities in which we live, work, learn, and play,” said Dawn Whaley, president and chief marketing officer of Sharecare. “The success of this initiative also highlights the power of partnership, and we are proud to work alongside SHBP, Anthem, CVS Caremark, UnitedHealthcare, Good Sports, and the Hawks to empower people across the Peach State to live healthier, happier lives.”

Grand prize winner #1: West End Elementary (Rome, GA)
Averaging nearly 585,000 steps per person over the 120 days of the challenge, West End Elementary led all participating schools, logging more than 102 million steps across 175 team members. One in four West End participants surpassed one million steps, and the school recorded the highest number of million-step achievers statewide. West End custodian Brenda Vandermark topped the school’s leaderboard with more than 3.4 million steps during the challenge, followed by teacher’s aide Kathryn Rains with more than 2.5 million steps, and Principal Dr. Dennis Drummond with more than 2.1 million steps. As the winning team in the Jump Shot for Health challenge, West End will receive a basketball court renovation³ and be celebrated at a special court unveiling ‘pep rally.’

Grand prize winner #2: Harmony Elementary (Monroe, GA)
With an average of 557,000 steps per participant, Harmony Elementary ranked second in Jump Shot for Health and will also receive a basketball court renovation³. Over the course of the challenge, Harmony achieved strong engagement across its 136 team members who walked a total of nearly 76 million steps. Twenty-two percent of participants exceeded one million steps, and the school’s weekly steps average increased by more than 76,000 during the final leg of the challenge. Tapping into the power of their school community, staff formed walking groups to promote daily activity, and one participant reported improved health outcomes that included no longer needing A1C medication. Top team contributors for Harmony included the school’s bookkeeper, Holly Roberts, with 2.4 million steps, and teachers Twilia Minshew and Cheryl Ebanks-Manning with 2.127 and 2.125 million steps, respectively.

“At Anthem, we believe healthy communities start with engaged individuals, and Jump Shot for Health is a perfect example,” said Robert Bunch, president of Anthem Blue Cross and Blue Shield of Georgia. “We’re proud to support this initiative that not only empowered State Health Benefit Plan members to prioritize their own well-being, but also helped create lasting, positive change for students in Georgia’s schools. It’s a win for personal health and a slam dunk for our communities.”

Three additional schools who competed in Jump Shot for Health will receive basketball equipment courtesy of the nonprofit Good Sports:

• Third place: Oakland Elementary School (McDonough, GA) with 477,649 average steps per participant; 69 participants walked a total of 32,957,822 steps
• Fourth place: Kipp Strive Academy (Atlanta, GA) with 452,023 average steps per participant; 50 participants walked a total of 22,601,165 steps
• Most improved: Annistown Elementary School (Snellville, GA) with 316,949 average steps per participant; 105 participants walked a total of 33,279,683 steps

“With each literal step they took throughout the Jump Shot for Health challenge, SHBP members across the state showed their unwavering commitment to fostering a positive campus experience for deserving young Georgians, and in the process, they demonstrably improved their personal well-being and inspired others to do the same,” said Louis Amis, executive director of SHBP, a division within the Georgia Department of Community Health. “We are grateful to the organizations that made this healthy competition possible, and are excited to unveil the grand prize winners’ fully renovated basketball courts in the upcoming academic schoolyear.”

Jump Shot for Health is made possible by the generous support of Sharecare, Anthem Blue Cross and Blue Shield of Georgia, CVS Caremark, UnitedHealthcare, Good Sports, and the Atlanta Hawks. SHBP members can continue engaging in well-being programs through the Sharecare app, available at https://bewellshbp.com/.

About Anthem Blue Cross and Blue Shield of Georgia
Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc., an independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. Additional information about Anthem Blue Cross and Blue Shield is available at www.anthem.com. Also, follow us at @AnthemBCBS on X or on LinkedIn.

About Sharecare 
Sharecare is a digital healthcare company that delivers software and tech-enabled services to stakeholders across the healthcare ecosystem to help improve care quality, drive better outcomes, and lower costs. Through its data-driven AI insights, evidence-based resources, and comprehensive platform – including benefits navigation, care management, home care resources, health information management, and more – Sharecare helps people easily and efficiently manage their healthcare and improve their well-being. Across its three business channels, Sharecare enables health plan sponsors, health systems and physician practices, and leading pharmaceutical brands to drive personalized and value-based care at scale. To learn more, visit www.sharecare.com.

Media Contact:
Sharecare PR Team
PR@sharecare.com

¹ Winners of Jump Shot for Health were determined by average step count per participant.
² https://www.gadoe.org/School-Improvement/Federal-Programs/title-i/Pages/Disadvantaged-Children.aspx
³ Scheduled in coordination with the school’s administration and academic calendar.

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7d0341b8-b759-40cc-aca6-86d569014fce

Parexel Announces AI Partnership with Weave Bio to Accelerate Regulatory Submission Processes




Parexel Announces AI Partnership with Weave Bio to Accelerate Regulatory Submission Processes

Collaboration leverages Parexel’s proven regulatory expertise and Weave Bio’s AI-native platform, aims to speed up market introduction of new therapies

RALEIGH, N.C., Sept. 30, 2025 (GLOBE NEWSWIRE) — Parexel, a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry today announced a partnership with Weave Bio, a pioneer in AI-native regulatory automation management solutions, aimed to accelerate regulatory submission processes and the time to market for new therapies. Under the agreement, Parexel will serve as Weave’s CRO design partner and will leverage Parexel’s extensive regulatory consulting expertise across clinical, non-clinical, clinical pharmacology and chemistry, manufacturing, and controls (CMC) to enhance Weave’s AI platform and product pipeline. In addition, Parexel will maintain a period of exclusivity as the only CRO licensed to use Weave’s innovative solutions after new products launch.

“This partnership represents a significant advancement in Parexel’s vision to leverage AI to speed clinical research processes, enhance first-time quality and accelerate the delivery of life-changing therapies to patients,” said Paul Bridges, President, Consulting, Parexel. “We’re beginning this partnership by addressing an area where sponsors feel extreme urgency – early regulatory authoring and submission preparation. By combining Weave’s cutting-edge AI technology with the human-in-the-lead expertise of Parexel Consulting, we’re helping teams move faster and with greater confidence while maintaining the highest levels of quality and compliance.”

Parexel has already leveraged Weave’s flagship offering, AutoIND, to support Investigational New Drug (IND) applications, and has been able to complete them 50% faster than traditional IND authoring timelines. These scalable efficiency gains enable high quality INDs to be developed at a transformative pace, supporting sponsors with the time-sensitive step of initiating new clinical trials sooner than current industry timelines. Weave’s AutoIND functionality is now part of Weave’s comprehensive regulatory workflow solution, The Weave Platform, that spans the entire regulatory lifecycle.

“AI tools are only as strong as the people behind them. Human experts provide the context that guides our platform and help translate its findings into action,” said Lindsay Mateo, Chief Commercial Officer at Weave. “Through this partnership, Weave will tap into Parexel’s deep regulatory expertise to refine and expand our solutions across the drug development industry.”

Parexel and Weave are presenting at the Regulatory Affairs Professionals Society (RAPS) Convergence on October 7-9 in Pittsburgh, Pennsylvania and will discuss the partnership during presentations and at their booths.

Parexel Booth: #606

Weave Bio Booth: #421

Thought leadership session: Speed Without Shortcuts: Navigating Regulatory Boundaries for AI Applications in Clinical Trials featuring

• Tala Fakhouri, Vice President Consulting, AI & Digital Policy, Real-World Research, Parexel
• Ryan Zettle, Head of Regulatory Submissions, Americas, Regulatory Consulting, Parexel

Sponsored Presentation: Lessons from a comparative analysis of old and new AI-infused regulatory processes

• Brandon Rice, CEO & Co-Founder

About Parexel 
Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™  We continue to earn recognition industrywide, including the 2024 Fierce Biotech CRO Award for “Innovative Approaches to Patient-Centric Research” and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships. For more information, visit parexel.com and follow us on LinkedIn, X, Facebook and Instagram.   

Media  
Danaka Williams 
+1 984 298 4207 
Danaka.Williams@parexel.com  

Addison Stallings 
+1 984 833 6362 
Addison.Stallings@parexel.com  

About Weave Bio
Weave Bio is an AI-native, cloud-based, software company that is redesigning regulatory workflows — transforming how novel therapies navigate the complex path from lab to clinic. The Weave Platform is an end-to-end solution that streamlines regulatory content preparation and lifecycle management for pharmaceutical companies, biotech firms, CROs, and regulatory consultants. Weave infuses AI into every step of the workflow, from data extraction to authoring to review and data verification, yielding compliant, submission-ready regulatory dossiers with speed.

The Weave Platform has been widely adopted for preclinical IND preparation and earned industry recognition as the “Biotech AI Innovation of the Year” award winner. Weave has since expanded capabilities across the platform to encompass clinical and approval-stage submissions, delivering a comprehensive AI workbench that accelerates regulatory timelines by over 50% while improving review quality and ensuring compliance with FDA, EMA, and global regulatory standards.

Founded in 2022 and headquartered in San Francisco, Weave bridges life sciences, regulatory expertise, AI innovation, and enterprise software to solve critical bottlenecks in drug development. For more information, visit weave.bio and follow us on LinkedIn.

Media  
Tammy Lyons
+1 314 548 3811
Tammy@weave.bio

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program




HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

Watch the “What This Means” video here

Featuring Company’s second-generation T-Cell Engager program
 and advantages over first-generation

Company’s T-Cell Engager program has made improvements in manufacturability, preclinical safety profile, and ability to treat a wide spectrum of solid tumors

MIRAMAR, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics, participated in a Virtual Investor “What This Means” segment.

As part of the segment, Dr. Rhode discussed the Company’s recent news announcing its TRBC-based second-generation T-Cell Engager (“TCE”) program and the positive safety profile from a non-human primate investigative study recently conducted by the Company for its TCE program. HCW Biologics believes its second-generation TCEs could alleviate the challenges of the first generation TCEs, such as complex manufacturing processes, tolerability, safety, antigen selection, and efficacy for solid tumors. The Company has joined a small group of innovative biotechnology companies who have discovered new TCEs that overcome resistance mechanisms and improve the ability to treat solid tumors.

The Virtual Investor “What This Means” segment featuring HCW Biologics is now available here.

About HCW Biologics:

HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients’ quality of life and potentially extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as many indications that impact quality-of-life that are not life-threatening. The Company’s lead product candidate, HCW9302, was developed using the Company’s legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics are being developed for treatment of a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform. Further preclinical evaluation studies are currently being conducted for these molecules the Company has selected based on promising preclinical data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/

Forward Looking Statements:

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include, the actual success and potency of the Company’s TCE-based TRBC fusion molecules; the ability of the Company’s TCE’s to target cancer antigens, CD3 activation of effector T cells, and reduce immunosuppression in the tumor microenvironment; the ability of the Company’s TCEs to exhibit potent and antigen-specific anti-pancreatic cancer activities both in vitro and in humanized mouse models; or whether the Company’s TCEs are effective in treatment of solid tumors and pancreatic cancers. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 28, 2025, the latest Form 10-Q filed with the SEC on August 18, 2025 and in other filings filed from time to time with the SEC.

Company Contact:
Dr. Peter Rhode
Chief Scientific Officer and Vice President of Clinical Operations
HCW Biologics Inc.
PeterRhode@HCWBiologics.com 

24/7 Market News: Sportswear and Smart Textiles are likely Key Spider Silk Target Markets for Kraig Labs




24/7 Market News: Sportswear and Smart Textiles are likely Key Spider Silk Target Markets for Kraig Labs

DENVER, Sept. 30, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, highlights the opportunity for recombinant spider silk produced by Kraig Biocraft Laboratories (OTCQB: KBLB), the global leader in the development and commercialization of spider silk. 24/7 Market News believes that some of the most obvious projected use-cases include compression gear, perspiration-wicking layers, temperature-regulating base layers, apparel for skiing, snowboarding, skateboarding, and contact sports.

Spider silk’s natural properties, lightweight toughness, high elasticity, breathability, and thermal regulation, make it particularly suitable for athletic settings. As more consumers seek gear that performs and aligns with sustainability, spider silk can offer performance advantages over synthetic textiles without the environmental downsides.

Kraig Labs is preparing to deliver the first spider silk samples to three apparel/gear companies, two of which are in the sports arena. These samples will probably be tested for durability, washability, moisture handling, and comfort, factors essential in demanding sports applications.

Smart textile enhancements, such as integrating sensors or responsive fibers (e.g., humidity-responsive contraction or cooling fabrics), may find spider silk an ideal base substrate due to its biocompatible, responsive properties. Academic research has shown spider silk-inspired fibers can exhibit supercontraction and responsive behavior under varying humidity conditions.

With a global technical textiles market valued at $200 billion in 2024 and projected to grow at a 5.2% CAGR through 2030, Kraig Labs is poised to disrupt traditional synthetics like polyester and nylon by offering sustainable, high-performance alternatives for athletic and smart fabric applications.

Emerging use cases include compression gear, moisture-wicking base layers, temperature-regulating apparel, and gear for high-impact sports such as skiing, snowboarding, skateboarding, cycling, and contact athletics. The demand for materials that combine technical performance, comfort, and sustainability continues to rise in the $400+ billion global sportswear market, driven by sustainability trends and performance innovation, creating a prime opportunity for KBLB’s scalable silk production.

Please click here to read the full Kraig Labs analyst report on 247marketnews.com.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications.

For more information, please visit: www.kraiglabs.com

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

About 24/7 Market News

24/7 Market News (24/7 MN) is a leading market news platform for public companies. As a pioneer in digital media, 24/7 MN is dedicated to the swift distribution of financial market news and information. 24/7 MN takes great pride in creating innovative public relations campaigns that help clients reach the target audience.

24/7 MARKET NEWS, INC (247) Disclaimer and Disclosure
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by one or more featured companies for providing ongoing KBLB market outreach and other services. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://247marketnews.com/kblb-disclosure/ for further KBLB and 247marketnews.com disclosure information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.